GNBT 1.74 Generex Biotechnology to Make Presentations At the American Diabetes Association's 67th Scientific Sessions
Jun 22, 2007 1:23:00 PM
2007 PrimeNewswire, Inc.
WORCESTER, Mass., June 22, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making three poster presentations at the American Diabetes Association's 67th Scientific Sessions in Chicago, IL June 22-26, 2007 (www.diabetes.org and www.scientificsessions.diabetes.org).
Two of the presentations feature the Company's proprietary confectionary Glucose RapidSpray(tm) product and its role in hypoglycemic control and as dietary supplement for weight control:
Glucose RapidSpray, A New Tool to Control Progression Towards Hypoglycaemia, by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy, with Antonio Picardi, Manon Yeganeh Khazrai, Maria Altomare, Natalia Visalli, and Elisa Cipponeri.
This study focuses on the importance of modulating hypoglycaemia, one of the factors in tight control of blood glucose to prevent complications. Most people with falling blood sugar overcompensate and run their blood glucose to extremely high levels, affording additional risks. Glucose RapidSpray used early in the onset of hypoglycaemia can stop the episode and prevent a further drop in blood glucose and the noxious feelings that ensue. Most important is the ability of the individual to specifically modulate glucose replacement only to the extent necessary.
Reduction of Body Weight Through Diet and the Use of Glucose RapidSpray, by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy with Manon Yeganeh Khazrai, Maria Altomare, Natalia Visalli, Laura Cipolloni, and Anna Rita Maurizi.
In this study, delivery of small amounts of glucose during the day appeared to reduce the body mass index (BMI) of subjects using Glucose RapidSpray as compared to a control group. This simple application may be a great boon to people with obesity and diabetes.
The other presentation features Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product:
Comparison of Pre-prandial s.c. Regular Insulin vs. Prandial Oral Insulin in Adult Type-1 DM Subjects Receiving Basal s.c. Twice Daily Isophane Insulin (NPH), by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador.
This study shows that the use of a simple system that delivers regular acting insulin to the lining of the mouth is non-inferior to insulin injection. The implication is important for millions of people of people with diabetes burdened by multiple daily injections. The delivery through the buccal mucosa is advantageous because of its enormous vascularity allowing for improved pharmacokinetics.
In addition, the following abstracts will appear in the Scientific Sessions Abstract Book:
6-Month Safety and Efficacy of Lunchtime Oral Insulin in Juvenile Type-1 DM Subjects Receiving Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner S.C. Regular Insulin, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs; and
Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy (CIT) and a 13-Point Method Designed to Enhance Compliance, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs.
The American Diabetes Association is the nation's leading 501(C)3 nonprofit health organization providing diabetes research, information, and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of communities. The mission of the Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To fulfill this mission, the American Diabetes Association funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The Association is also actively involved in advocating for scientific research and for the rights of people with diabetes.
The Scientific Sessions are held in June each year and provide an opportunity for members of the diabetes community from around the world to participate in the largest annual research and clinical meeting on diabetes. Sessions focus on the latest information in the areas of basic and clinical research and on the application of this information to clinical practice. The program includes symposia, oral and poster abstract presentations, interactive workshops, poster discussions, and other small group learning sessions.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: Generex
Shayne Gilliatt
800-391-6755
416-364-2551
CEOcast, Inc.
Andrew Hellman
212-732-4300
AI
News 
Market Data 
Discover 
